| Year |
Citation |
Score |
| 2023 |
Gaba AG, Cao L, Renfrew RJ, Witte D, Wernisch JM, Sahmoun AE, Goel S, Egland KA, Crosby RD. The Impact of Medicaid Expansion Under the Affordable Care Act on the Gap Between American Indians and Whites in Breast Cancer Management and Prognosis. Clinical Breast Cancer. PMID 38171945 DOI: 10.1016/j.clbc.2023.11.006 |
0.439 |
|
| 2023 |
Gaba AG, Cao L, Renfrew RJ, Witte D, Wernisch JM, Sahmoun AE, Goel S, Egland KA, Crosby RD. Differences in Breast Cancers Among American Indian/Alaska Native and non-Hispanic Whites in the USA. Journal of Racial and Ethnic Health Disparities. PMID 37432561 DOI: 10.1007/s40615-023-01704-4 |
0.433 |
|
| 2020 |
Sheets JN, Patrick ME, Egland KA. expression correlates with decreased metastasis and increased survival in a high-grade serous ovarian cancer xenograft murine model. Oncotarget. 11: 2290-2301. PMID 32595828 DOI: 10.18632/Oncotarget.27626 |
0.519 |
|
| 2019 |
Patrick ME, Egland KA. SUSD2 Proteolytic Cleavage Requires the GDPH Sequence and Inter-Fragment Disulfide Bonds for Surface Presentation of Galectin-1 on Breast Cancer Cells. International Journal of Molecular Sciences. 20. PMID 31387209 DOI: 10.3390/Ijms20153814 |
0.577 |
|
| 2018 |
Lager TW, Roetman JJ, Kunkel J, Thacker M, Sheets JN, Egland KA, Miles CM, Larson MK, Gubbels JAA. Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells. Platelets. 1-4. PMID 30335544 DOI: 10.1080/09537104.2018.1530345 |
0.424 |
|
| 2018 |
Evans RL, Pottala JV, Nagata S, Egland KA. Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality. Bmc Cancer. 18: 119. PMID 29386014 DOI: 10.1186/S12885-018-4022-5 |
0.548 |
|
| 2017 |
Hultgren EM, Patrick ME, Evans RL, Stoos CT, Egland KA. SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer. Plos One. 12: e0177089. PMID 28475599 DOI: 10.1371/Journal.Pone.0177089 |
0.553 |
|
| 2016 |
Sheets JN, Iwanicki M, Liu JF, Howitt BE, Hirsch MS, Gubbels JA, Drapkin R, Egland KA. SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis. 5: e264. PMID 27775699 DOI: 10.1038/oncsis.2016.64 |
0.464 |
|
| 2015 |
Sheets JN, Iwanicki M, Liu J, Drapkin R, Egland KA. Abstract POSTER-BIOL-1345: SUSD2 inhibits spheroids from breaching the mesothelium: a mechanism for increased longevity of patients with SUSD2-expressing high-grade ovarian serous carcinoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1345 |
0.518 |
|
| 2015 |
Lager T, Thacker M, Etrheim C, Egland KA, Larson MK, Gubbels JAA. Abstract 301A: A novel epithelial ovarian cancer protein, SUSD2, inhibits platelet activation and binding to tumor cells Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-301A |
0.456 |
|
| 2014 |
Evans RL, Pottala JV, Egland KA. Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prevention Research (Philadelphia, Pa.). 7: 545-55. PMID 24641868 DOI: 10.1158/1940-6207.Capr-13-0416 |
0.647 |
|
| 2013 |
Watson AP, Evans RL, Egland KA. Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis. Molecular Cancer Research : McR. 11: 74-85. PMID 23131994 DOI: 10.1158/1541-7786.Mcr-12-0501-T |
0.679 |
|
| 2013 |
Gubbels JAA, Hultgren EM, Johnson J, Johnson E, Sachs J, Hirsch MS, Liu J, Drapkin R, Egland KA. Abstract A71: Expression of Sushi Domain Containing 2 (SUSD2) in high-grade ovarian serous carcinoma correlated with increased longevity of patients Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A71 |
0.462 |
|
| 2011 |
Watson AP, Gubbels JAA, Egland KA. Abstract 3054: Sushi domain containing 2 (SUSD2): A plasma membrane protein on breast cancer cells that interacts with galectin-1 Cancer Research. 71: 3054-3054. DOI: 10.1158/1538-7445.Am2011-3054 |
0.69 |
|
| 2010 |
Watson AP, Egland KA. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers. South Dakota Medicine : the Journal of the South Dakota State Medical Association. 63: 247-53. PMID 20666024 |
0.652 |
|
| 2008 |
Rieck LD, Pottala JV, Eliason SL, Koch MR, Egland PG, Egland KA. Status of HER-2 gene amplification in breast cancers from Native American women. Cancer Genetics and Cytogenetics. 187: 54-6. PMID 18992644 DOI: 10.1016/J.Cancergencyto.2008.08.004 |
0.572 |
|
| 2006 |
Egland KA, Liu XF, Squires S, Nagata S, Man YG, Bera TK, Onda M, Vincent JJ, Strausberg RL, Lee B, Pastan I. High expression of a cytokeratin-associated protein in many cancers. Proceedings of the National Academy of Sciences of the United States of America. 103: 5929-34. PMID 16585525 DOI: 10.1073/Pnas.0601296103 |
0.624 |
|
| 2006 |
Korherr C, Gille H, Schäfer R, Koenig-Hoffmann K, Dixelius J, Egland KA, Pastan I, Brinkmann U. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proceedings of the National Academy of Sciences of the United States of America. 103: 4240-5. PMID 16537515 DOI: 10.1073/Pnas.0511319103 |
0.366 |
|
| 2003 |
Egland KA, Vincent JJ, Strausberg R, Lee B, Pastan I. Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proceedings of the National Academy of Sciences of the United States of America. 100: 1099-104. PMID 12538848 DOI: 10.1073/Pnas.0337425100 |
0.66 |
|
| 2002 |
Egland KA, Kumar V, Duray P, Pastan I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Molecular Cancer Therapeutics. 1: 441-50. PMID 12479262 |
0.471 |
|
| Show low-probability matches. |